Clinical Trial Update: Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing once-daily Fluticasone Furoate/Vilanterol to twice-daily Fluticasone Propionate/Salmeterol in COPD; completed with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone furoate/vilanterol inhalation powder 100/25 mcg (fluticasone furoate/vilanterol)
• Fluticasone propionate/salmeterol inhalation powder 250/50 mcg (fluticasone propionate/salmeterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-02-06